Guidance

Biopharmaceutical manufacturing and product development

This guidance was withdrawn on

PHE’s clinical drug development and production capability was transferred to Porton Biopharma Limited in 2015. See Porton Biopharma website.

Information on PHE's own biopharmaceutical products including the UK’s anthrax vaccine and Erwinase™ and Erwinaze™.